IL2 and metastatic melanoma: Additionally, a US claims‐based study, which included nearly 1000 metastatic melanoma patients treated with systemic therapy, revealed varied use of treatments across all lines, with temozolomide being the most commonly used in both first‐ and second‐line settings (39% and 21%, respectively); paclitaxel, carboplatin, dacarbazine, interferon‐α, and IL‐2 were also used in 14–22% of patients across all lines 18.